Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02688790 · ClinicalTrials.gov registry record · Phase 1
Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection
A Phase 1 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02688790 is a Phase 1 study that was terminated before completion, run by AbbVie. The registered enrollment target is 8 participants.
The verdict
NCT02688790, a Phase 1 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the Pharmacokinetic (PK) profile of a single intravenous (IV) infusion dose of dalbavancin, and to evaluate the safety and tolerability of a single dalbavancin IV infusion.
Interventions
- DRUG Dalbavancin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-04-01 |
| Est. Completion | 2019-04-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02688790
The ClinicalTrials.gov registry entry for NCT02688790 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dalbavancin is the first listed.
NCT02688790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02688790 about?
NCT02688790 is a clinical study titled "Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection". The purpose of this study is to evaluate the Pharmacokinetic (PK) profile of a single intravenous (IV) infusion dose of dalbavancin, and to evaluate the safety and tolerability of a single dalbavancin IV infusion.
What is the current status of trial NCT02688790?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2016-04-01. Estimated completion is 2019-04-03.
What interventions are being tested in trial NCT02688790?
The interventions under investigation include: Dalbavancin (DRUG).
Who is sponsoring clinical trial NCT02688790?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.